The expression of anamorsin in diffuse large B cell lymphoma: Possible prognostic biomarker for low IPI patients
Authors:
- Hirohiko ShibayamaHSHirohiko Shibayama
- Shinsuke MurataSMShinsuke Murata
- Yuri SaitohYSYuri Saitoh
- Yuna SugimotoYSYuna Sugimoto
- Itaru MatsumuraIMItaru Matsumura
- Hiroyasu OgawaHOHiroyasu Ogawa
- Haruo SugiyamaHSHaruo Sugiyama
- Shirou FukuharaSFShirou Fukuhara
- Masayuki HinoMHMasayuki Hino
- Akihisa KanamaruAKAkihisa Kanamaru
- Amane YamauchiAYAmane Yamauchi
- 1 January 2008
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (1) , 113-121
Abstract
Anamorsin is a cell-death-defying factor, which was originally isolated as a molecule that conferred resistance to apoptosis induced by growth factor starvation. In order to evaluate anamorsin expression levels in malignant lymphoma, we immunostained paraffin-embedded sections with anti-anamorsin monoclonal antibodies. About 40% (89/234) of sections from patients with diffuse large B cell lymphoma (DLBCL) showed strong anamorsin expression. Comparing the level of anamorsin expression in DLBCL patients with their clinical features (i.e., overall survival rate, International Prognostic Index (IPI) parameters, and treatment response) revealed no significant correlation between anamorsin expression levels and these clinical features. However, anamorsin expression in DLBCL patients with a low IPI was shown to be an unfavorable biomarker, especially in the patients who received chemotherapy without rituximab. It is suggested that anamorsin might play some roles in the abnormal growth of DLBCL.Keywords
This publication has 23 references indexed in Scilit:
- New Drugs for the Treatment of Advanced-Stage Diffuse Large Cell LymphomasSeminars in Hematology, 2006
- Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entitiesLeukemia, 2006
- Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative studyBlood, 2006
- BCL2 Expression Is a Prognostic Marker for the Activated B-Cell–Like Type of Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2006
- Biomarkers of potential prognostic significance in diffuse large B‐cell lymphomaCancer, 2005
- Bcl-2 antisense therapy in B-cell malignanciesBlood Reviews, 2005
- CD10 and Bcl‐2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large‐cell lymphoma with very good or very poor prognosesHistopathology, 2005
- WT1 as a Universal Marker for Minimal Residual Disease Detection and Quantification in Myeloid Leukemias and in Myelodysplastic SyndromeActa Haematologica, 2004
- Identification of a Cytokine-induced Antiapoptotic Molecule Anamorsin Essential for Definitive HematopoiesisJournal of Experimental Medicine, 2004
- Imatinib Mesylate — A New Oral Targeted TherapyNew England Journal of Medicine, 2002